The current status in hematopoietic stem cell mobilization

Journal of Clinical Apheresis

Volumn 30, Issue 5, 2015, Pages 273-280

  Civriz Bozdag, Sinem ^a   Tekgunduz, Emre ^b   Altuntas, Fevzi ^b  

^a ANKARA UNIVERSITY   (Turkey)

^b Ankara Oncology Training Hospital   (Turkey)

Author keywords

stem cell mobilization

Indexed keywords

BETAFECTIN; BORTEZOMIB; CD135 ANTIGEN; CD150 ANTIGEN; CD34 ANTIGEN; CD48 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FILGRASTIM; FLUDARABINE; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH HORMONE; LENALIDOMIDE; LENOGRASTIM; MELPHALAN; PEGFILGRASTIM; PLERIXAFOR; POLYSACCHARIDE SULFATE; PROTEIN INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SARGRAMOSTIM; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; T 134; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4; ANTINEOPLASTIC AGENT; BIOLOGICAL FACTOR; CXCR4 PROTEIN, HUMAN; HETEROCYCLIC COMPOUND; PARATHYROID HORMONE; RECOMBINANT PROTEIN;

ABDOMINAL PAIN; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL COUNT; CELL FUNCTION; CELLULAR DISTRIBUTION; CLINICAL EFFECTIVENESS; DRUG SAFETY; FEBRILE NEUTROPENIA; HEADACHE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKOCYTE COUNT; LYMPHOMA; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; STEM CELL MOBILIZATION; UNSPECIFIED SIDE EFFECT; VOMITING; ANIMAL; ANTAGONISTS AND INHIBITORS; CYTAPHERESIS; DRUG EFFECTS; MOUSE; PHYSIOLOGY; PROCEDURES;

ANIMALS; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BIOLOGICAL FACTORS; BORTEZOMIB; CYTAPHERESIS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; INTEGRIN ALPHA4BETA1; MICE; PARATHYROID HORMONE; RECEPTORS, CXCR4; RECOMBINANT PROTEINS;

EID: 84944355545     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21374     Document Type: Article

References (92)

1. Morrison S, Sacdden D,. The bone marrow niche for haematopoietic stem cells. Nature 2014; 505: 327-334.
2. Kiel MJ, Radice GL, Morrison SJ,. Lack of evidence that hematopoietic stem cells depend on N-cadherin-mediated adhesion to osteoblasts for their maintenance. Cell Stem Cell 2007; 1: 204-217.
3. Nombela-Arrieta C, Pivarnik G, Winkel B, Canty KJ, Harley B, Mahoney JE, Park SY, Lu J, Protopopov A, Silberstein LE,. Quantitative imaging of haematopoietic stem and progenitor cell localization and hypoxic status in the bone marrow microenvironment. Nat Cell Biol 2013; 15: 533-543.
4. Kiel MJ, Yilmaz OH, Iwashita T, Terhorst C, Morrison SJ,. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005; 121: 1109-1121.
5. Bonig H, Papayannopoulos T,. Hematopoietic stem cell mobilization: updated conceptual Renditions. Leukemia 2013; 27: 24-31.
6. Ellis SL, Grassinger J, Jones A, Borg J, Camenisch T, Haylock D, Bertoncello I, Nilsson SK,. The relationship between bone, hemopoietic stem cells, and vasculature. Blood 2011; 118: 1516-1524.
7. Sugiyama T, Kohara H, Noda M, Nagasawa T,. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006; 25: 977-988.
8. Kiel MJ, Morrison SJ,. Maintaining hematopoietic stem cells in the vascular niche. Immunity 2006; 25: 862-864.
9. Kiel MJ, Morrison SJ,. Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol 2008; 8: 290-301. Review.
10. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT,. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425: 841-846.
11. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ, Harris S, Wiedemann LM, Mishina Y, Li L,. Identification of the hematopoietic stem cell niche and control of the niche size. Nature 2003; 425: 836-841.
12. Thorén LA, Liuba K, Bryder D, Nygren JM, Jensen CT, Qian H, Antonchuk J, Jacobsen SE,. Kit regulates maintenance of quiescent hematopoietic stem cells. J Immunol 2008; 180: 2045-2053.
13. Ara T, Tokoyoda K, Sugiyama T, Egawa T, Kawabata K, Nagasawa T,. Long-term hematopoietic stem cells require stromal cell-derived factor-1 for colonizing bone marrow during ontogeny. Immunity 2003; 19: 257-267.
14. Papayannopoulou T, Craddock C, Nakamoto B, Priestley GV, Wolf NS,. The VLA-4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci USA 1995; 92: 9647-9651.
15. Peled A, Kollet O, Ponomaryov T, Petit I, Franitza S, Grabovsky V, Slav MM, Nagler A, Lider O, Alon R, Zipori D, Lapidot T,. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34 cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 2000; 95: 3289-3296.
16. Alvarez B, Vazguez A, Larrea C,. Mobilization and Homing of Hematopoietic Stem Cells. Stem Cell Transplantation. Landes Bioscience and Springer Science+Business Media; 2012. pp 152-167.
17. Fox M, Lapidot T, Petit I, Kollet O, DiPersio J, Link D, Devine S,. Stem cell mobilization. Hematology 2003.
18. Hattori K, Heissig B, Tashiro K, Honjo T, Tateno M, Shieh JH, Hackett NR, Quitoriano MS, Crystal RG, Rafii S, Moore MA,. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001; 97: 3354-3360.
19. Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ,. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001; 98: 1289-1297.
20. Yu X, Huang Y, Collin-Osdoby P, Osdoby P,. Stromal cell derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res 2003; 18: 1404-1418.
21. Marques JF1, Vigorito AC, Aranha FJ, Lorand-Metze I, Miranda EC, Lima Filho EC, Valbonesi M, Santini G, De Souza CA,. Early total white blood cell recovery is a predictor of low number of apheresis and good CD34(+) cell yield. Transfus Sci 2000; 23: 91-100.
22. Pérez-Simõn JA, Martín A, Caballero D, Corral M, Nieto MJ, Gonzalez M, Vazquez L, Lõpez-Berges C, Cañizo MC, Mateos MV, Orfao A, San Miguel JF,. Clinical significance of CD34 cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24: 1279-1283.
23. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W,. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration ofmyeloablative chemotherapy. Blood 1995; 86: 3961-3969.
24. Ketterer N, Salles G, Raba M, Espinouse D, Sonet A, Tremisi P, Dumontet C, Moullet I, Eljaafari-Corbin A, Neidhardt-Berard EM, Bouafia F, Coiffier B,. High CD34 cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148-3155.
25. Chang YJ, Xu LP, Liu DH, Liu KY, Han W, Chen YH, Yu-Wang, Chen H, Wang JZ, Zhang XH, Zhao XY, Huang XJ,. Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status. Biol Blood Marrow Transplant 2009; 15: 632-638.
26. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K, Goldschmidt H, Ho AD,. Poor mobilization of hematopoietic stem cells definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010; 16: 490-499.
27. Demiriz IS, Bozdag SC, Tekgündüz E, Uʇur B, Durgun G, Koçubaba S, Altuntaş F,. Predicting the successful peripheral blood stem cell harvesting. Transfus Apher Sci 2013; 48: 411-414.
28. Ford CD, Green W, Warenski S, Petersen FB,. Effect of prior chemotherapy on hematopoietic stem cell mobilization. Bone Marrow Transplant 2004; 33: 901-905.
29. Akhtar S, Weshi AE, Rahal M, et al., Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 68 patients. Leuk Lymphoma 2008; 49: 769-778.
30. Kuittinen T, Nousiainen T, Halonen P, Mahlamäki E, Jantunen E,. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 907-912.
31. Kuittinen T, Nousiainen T, Halonen P, Mahlamäki E, Jantunen E,. Factors affecting hematopoietic progenitor cell mobilization: an analysis of 307 patients. Transfus Apher Sci 2008; 39: 187-192.
32. Fruehauf S, Seggewiss R,. It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement. Br J Haematol 2003; 122: 360-375.
33. Gambell P, Herbert K, Dickinson M, Stokes K, Bressel M, Wall D, Harrison S, Prince HM,. Peripheral blood CD34 cell enumeration as a predictor of apheresis yield: an analysis of over 1000 collections. Biol Blood Marrow Transplant 2012; 18: 763-772.
34. Ferraro F, Lymperi S, Méndez-Ferrer S, Saez B, Spencer JA, Yeap BY, Masselli E, Graiani G, Prezioso L, Rizzini EL, Mangoni M, Rizzoli V, Sykes SM, Lin CP, Frenette PS, Quaini F, Scadden DT,. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med 2011; 3: 104ra101.
35. Ford CD, Lehman C, Strupp A, Kelley L,. Comparison of CD34 cell collection efficiency on the COBE Spectra and Fenwal CS-3000 Plus. J Clin Apher 2002; 17: 17-20.
36. Smolowicz AG, Villman K, Tidefelt U,. Large-volume apheresis for the harvest of peripheral blood progenitor cells for autologous transplantation. Transfusion 1997; 37: 188-192.
37. Abrahamsen JF, Stamnesfet S, Liseth K, Hervig T, Bruserud O,. Large-volume leukapheresis yields more viable CD34 cells and colony-forming units than normal-volume leukapheresis, especially in patients who mobilize low numbers of CD34 cells. Transfusion 2005; 45: 248-253.
38. Olivieri A, Marchetti M, Lemoli R, Tarella C, Iacone A, Lanza F, Rambaldi A, Bosi A,; Italian Group for Stem Cell Transplantation. Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo italianoTrapianto di Midollo Osseo. Bone Marrow Transplant 2012; 47: 342-351.
39. Pierelli L, Perseghin P,. Plerixafor (Mozobil) and other mobilizing agents. Transfus Apher Sci 2013; 48: 133-135.
40. Petit I, Szyper-Kravitz M, Nagler A, et al., G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3: 687-694.
41. Weaver CH, Birch R, Greco FA, Schwartzberg L, McAneny B, Moore M, et al., Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol 1998; 100: 338-347.
42. Demirer T, Ayli M, Ozcan M, Gunel N, Haznedar R, Dagli M, et al., Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002; 116: 468-474.
43. Anderlini P, Donato M, Lauppe MJ, et al., A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34 peripheral blood progenitor cells in normal donors. Br J Haematol 2000; 109: 770-777.
44. Lefrère F, Audat F, Hermine O, Cavazzana-Calvo M, Belanger C, Arnulf B, Buzyn A, Varet B,. The timing of granulocyte-colony-stimulating factor administration after chemotherapy does not affect stem and progenitor cell apheresis yield: a retrospective study of 65 cases. Transfusion 1999; 39: 561-564.
45. Stewart DA1, Guo D, Morris D, Poon MC, Ruether BA, Jones AR, Klassen J, Auer I, Luider J, Chaudhry A, Brown C, Russell JA,. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Bone Marrow Transplant 1999; 23: 111-117.
46. Ozcelik T, Topcuoglu P, Beksac M, Ozcan M, Arat M, Biyikli Z, Bakanay SM, Ilhan O, Gurman G, Arslan O, Demirer T,. Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF. Bone Marrow Transplant 2009; 44: 779-783.
47. Pérez-Lõpez O, Martín-Sánchez J, Parody-Porras R, Espigado-Tocino I, Noguerol P, Carmona-González M, Pérez-Simõn JA,. Lenograstim compared to filgrastim for the mobilization of hematopoietic stem cells in healthy donors. Transfusion 2013; 53: 3240-3242.
48. Ria R, Gasparre T, Mangialardi G, Bruno A, Iodice G, Vacca A, Dammacco F,. Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs. Bone Marrow Transplant 2010; 45: 277-281.
49. Ataergin S, Arpaci F, Turan M, Solchaga L, Cetin T, Ozturk M, Ozet A, Komurcu S, Ozturk B,. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation. Am J Hematol 2008; 83: 644-648.
50. Sivgin S, Karakus E, Kaynar L, Kurnaz F, Pala C, Keklik M, Zararsiz G, Solmaz M, Eser B, Cetin M, Unal A,. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey. Transfus Apher Sci 2013; 48: 315-320.
51. Isidori A, Tani M, Bonifazi F, Zinzani P, Curti A, Motta MR, Rizzi S, Giudice V, Farese O, Rovito M, Alinari L, Conte R, Baccarani M, Lemoli RM,. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005; 90: 225-231.
52. Tricot G, Barlogie B, Zangari M, van Rhee F, Hoering A, Szymonifka J, Cottler-Fox M,. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. Haematologica 2008; 93: 1739-1742.
53. Simona B, Cristina R, Luca N, Sara S, Aleksandra B, Paola B, Federica G, Pierluigi A, Laura O, Simona S, Jessica Q, Mara N, Giovanni M,. A single dose of pegfilgrastim versus daily filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy. Transfus Apher Sci 2010; 43: 321-326.
54. Weaver CH, Schulman KA, Buckner CD,. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Bone Marrow Transplant 2001; 27 (Suppl 2): S23-S29.
55. Milone G1, Leotta S, Indelicato F, Mercurio S, Moschetti G, Di Raimondo F, Tornello A, Consoli U, Guido G, Giustolisi R,. G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment. Bone Marrow Transplant 2003; 31: 747-754.
56. Gertz MA1, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Gastineau DA, Winters JL, Litzow MR,. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 2009; 43: 619-625.
57. Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, Shaughnessy P, Snyder E, Bensinger W, Copelan E, Hosing C, Negrin R, Petersen FB, Rondelli D, Soiffer R, Leather H, Pazzalia A, Devine S,. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant 2014; 20: 295-308.
58. Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P, Liso V,. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 285-290.
59. Lee JL, Kim S, Kim SW, Kim EK, Kim SB, Kang YK, Lee J, Kim MW, Park CJ, Chi HS, Huh J, Kim SH, Suh C,. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplant 2005; 35: 449-454.
60. DiPersio JF, Ho AD, Hanrahan J, Hsu FJ, Fruehauf S,. Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting. Biol Blood Marrow Transplant 2011; 17: 943-955.
61. Pozotrigo M, Adel N, Landau H, Lesokhin A, Lendvai N, Chung DJ, Chimento D, Riedel E, Chen X, Reich L, Comenzo R, Giralt S, Hassoun H,. Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center. Bone Marrow Transplant 2013; 48: 1033-1039.
62. Kumar S1, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Richardson PG, Durie BG, Rajkumar SV,; International Myeloma Working Group. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009; 114: 1729-1735.
63. Hamadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, Watkins K, Morrison D, Speir E, Deremer D, Kota V, Jillella A, Craig M, Awan F,. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Biol Blood Marrow Transplant 2012; 18: 1128-1135.
64. Petrucci MT, Avvisati G, La Verde G, De Fabritiis P, Ribersani M, Palumbo G, De Felice L, Rusignuolo A, Simone F, Meloni G, Mandelli F,. Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cells in patients with multiple myeloma. Acta Haematol 2003; 109: 184-188.
65. Larochelle A, Krouse A, Metzger M, Orlic D, Donahue RE, Fricker S, Bridger G, Dunbar CE, Hematti P,. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 2006; 107: 3772-3778.
66. Fruehauf S, Veldwijk MR, Seeger T, Schubert M, Laufs S, Topaly J, Wuchter P, Dillmann F, Eckstein V, Wenz F, Goldschmidt H, Ho AD, Calandra G,. A combination of granulocytecolony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European Phase II study. Cytotherapy 2009; 11: 992-1001.
67. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Früehauf S, Horwitz M, Cooper D, Bridger G, Calandra G,; 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
68. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G,; 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-4773.
69. Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, Hsu FJ, Bridger G, Bolwell BJ,. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biol Blood Marrow Transplant 2012; 18: 1564-1572.
70. Shaughnessy P, Uberti J, Devine S, Maziarz RT, Vose J, Micallef I, Jacobsen E, McCarty J, Stiff P, Artz A, Ball ED, Berryman R, Dugan M, Joyce R, Hsu FJ, Johns D, McSweeney P,. Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program. Bone Marrow Transplant 2013; 48: 777-7781.
71. Cashen A, Lopez S, Gao F, Calandra G, MacFarland R, Badel K, DiPersio,. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 1253-1261.
72. Malard F, Kröger N, Gabriel IH, Hübel K, Apperley JF, Basak GW, Douglas KW, Geraldes C, Jaksic O, Koristek Z, Lanza F, Lemoli R, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF,. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Biol Blood Marrow Transplant 2012; 18: 314-317.
73. Duarte RF, Shaw BE, Marín P, Kottaridis P, Ortiz M, Morante C, Delgado J, Gayoso J, Goterriz R, Martínez-Chamorro C, Mateos-Mazõn JJ, Ramírez C, de la Rubia J, Achtereekte H, Gandhi PJ, Douglas KW, Russell NH,. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011; 46: 52-58.
74. Fowler CJ, Dunn A, Hayes-Lattin B, Hansen K, Hansen L, Lanier K, Nelson V, Kovacsovics T, Leis J, Calandra G, Maziarz RT,. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 2009; 43: 909-917.
75. Micallef IN, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM, Bridger G, Calandra G,. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009; 15: 1578-1586.
76. Hübel K, Fresen MM, Apperley JF, Basak GW, Douglas KW, Gabriel IH, Geraldes C, Jaksic O, Koristek Z, Kröger N, Lanza F, Lemoli RM, Mikala G, Selleslag D, Worel N, Mohty M, Duarte RF,. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. Bone Marrow Transplant 2012; 47: 1046-1050.
77. Tekgündüz E, Altuntaş F, Sbox drawings light down and leftvgbox drawings light down and leftn S, Akbox drawings light down and left SZ, Dönmez A, Topçuoʇlu P, Ybox drawings light down and leftldbox drawings light down and leftrbox drawings light down and leftm R, Baysal NA, Ayybox drawings light down and leftldbox drawings light down and leftz E, Yüksel MK, Sarbox drawings light down and left I, Tombuloʇlu M, Unal A, Ilhan O,. Plerixafor use in patients with previous mobilization failure: a multicenter experience. Transfus Apher Sci 2012; 47: 77-80.
78. Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K, Dehner C, Gibney C, Bridger G, Calandra G,. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010; 45: 39-47.
79. Attolico I, Pavone V, Ostuni A, Rossini B, Musso M, Crescimanno A, Martino M, Iacopino P, Milone G, Tedeschi P, Coluzzi S, Nuccorini R, Pascale S, Di Nardo E, Olivieri A,. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant 2012; 18: 241-249.
80. Costa LJ, Miller AN, Alexander ET, Hogan KR, Shabbir M, Schaub C, Stuart RK,. Growth factor and patient adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant 2011; 46: 523-528.
81. Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, Langston A, Prichard JM, Anderson D, Gleason C, Lonial S, Flowers CR, Kaufman JL, Waller EK,. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 2011; 51: 2175-2182.
82. Hauge AW, Haastrup EK, Sengeløv H, Minulescu L, Dickmeiss E, Fischer-Nielsen A,. Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation. Transfusion 2014; 54: 1055-1058.
83. Duan D1, Xiao B, Yang S, Shao Z, Wang H, Guo X, Liu Y, Ye Z,. Mobilization efficiency of granulocyte colony-stimulating factor and stem cell factor to bone marrow mononuclear cells and mechanisms. J Huazhong Univ Sci Technol Med Sci 2010; 30: 477-481.
84. Herbert KE, Morgan S, Prince HM, Westerman DA, Wolf MM, Carney DA, Yuen K, di Iulio J, Seymour JF,. Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator. Leukemia 2009; 23: 305-312.
85. Dawson MA, Schwarer AP, Muirhead JL, Bailey MJ, Bollard GM, Spencer A,. Successful mobilization of peripheral blood stem cells using recombinant human stem cell factor in heavily pretreated patients who have failed a previous attempt with a granulocyte colony-stimulating factor-based regimen. Bone Marrow Transplant 2005; 36: 389-396.
86. Carlo-Stella C, Di Nicola M, Milani R, Guidetti A, Magni M, Milanesi M, Longoni P, Matteucci P, Formelli F, Ravagnani F, Corradini P, Gianni AM,. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. Blood 2004; 103: 3287-3295.
87. Linker C, Anderlini P, Herzig R, Christiansen N, Somlo G, Bensinger W, Fay J, Lynch JP, Goodnough LT, Ashby M, Benyunes MC, Jones DV, Yang TA, Miller LL, Weaver C,. Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. Biol Blood Marrow Transplant 2003; 9: 405-413.
88. Brunner S, Zaruba MM, Huber B, David R, Vallaster M, Assmann G, Mueller-Hoecker J, Franz WM,. Parathyroid hormone effectively induces mobilization of progenitor cells without depletion of bone marrow. Exp Hematol 2008; 36: 1157-1166.
89. Abraham M, Biyder K, Begin M, Wald H, Weiss ID, Galun E, Nagler A, Peled A,. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells 2007; 25: 2158-2166.
90. Arakaki R, Tamamura H, Premanathan M, Kanbara K, Ramanan S, Mochizuki K, Baba M, Fujii N, Nakashima H,. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J Virol 1999; 73: 1719-1723.
91. Pelus LM, Bian H, Fukuda S, Wong D, Merzouk A, Salari H,. The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor. Exp Hematol 2005; 33: 295-307.
92. Neumann F, Zohren F, Haas R,. The role of natalizumab in hematopoietic stem cell mobilization. Expert Opin Biol Ther 2009; 9: 1099-1106.